LIVN (LivaNova) Research & Development: $207 Mil (TTM As of Mar. 2026)


LIVN LivaNova PLC LIVN
76 GF Score
Price $81.05
GF Value $62.48
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is LivaNova Research & Development?

LivaNova LIVN +1.40% 76 Research & Development is $207 Mil as of Mar. 2026. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. LivaNova's Research & Development for the three months ended in Mar. 2026 was $59 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $207 Mil.

LivaNova  (NAS:LIVN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LivaNova Research & Development Related Terms

LivaNova Research & Development Historical Data

* Premium members only.

The historical data trend for LivaNova's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LivaNova Research & Development Chart

LivaNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 183.41 155.81 193.82 182.51 185.76

LivaNova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.88 47.19 48.58 52.12 58.70
LIVN
76GF Score
LivaNova PLC LIVN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LivaNova Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $207 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $207 Mil mean?
LivaNova (LIVN) has a Research & Development of $207 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on LivaNova and its competitors.
Is LivaNova's Research & Development too high?
LivaNova's current Research & Development is $207 Mil. Overall, LivaNova has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's Research & Development compare to IRTC and HAE?
LivaNova's Research & Development of $207 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LivaNova and its competitors. LivaNova's current Research & Development is $207 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $62.48, compared to a current price of $81.05 — trading 29.7% above its estimated fair value. The current Research & Development is $207 Mil. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LivaNova (LIVN), the current Research & Development is $207 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LivaNova (LIVN) Overvalued in 2026?

Based on GuruFocus' analysis, LivaNova stock appears to be overvalued. The current stock price of $81.05 is trading 29.7% above its estimated GF Value™ of $62.48. GuruFocus considers LivaNova to be Modestly Overvalued.

Key valuation signals for LIVN:

  • Research & Development: $207 Mil
  • GF Value™: $62.48 vs. price of $81.05 (29.7% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LivaNova Business Description

Other Exchanges LIA:Germany
Address 20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score

Get the complete analysis for LIVN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.05
Price
$62.48
GF Value